Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand

Simple item page
dc.contributor.authorJee, A.S.
dc.contributor.authorSheehy, R.
dc.contributor.authorHopkins, P.
dc.contributor.authorCorte, T.J.
dc.contributor.authorGrainge, C.
dc.contributor.authorTroy, L.K.
dc.contributor.authorSymons, K.
dc.contributor.authorSpencer, L.M.
dc.contributor.authorReynolds, P.N.
dc.contributor.authorChapman, S.
dc.contributor.authorde Boer, S.
dc.contributor.authorReddy, T.
dc.contributor.authorHolland, A.E.
dc.contributor.authorChambers, D.C.
dc.contributor.authorGlaspole, I.N.
dc.contributor.authorJo, H.E.
dc.contributor.authorBleasel, J.F.
dc.contributor.authorWrobel, J.P.
dc.contributor.authorDowman, L.
dc.contributor.authorParker, M.J.S.
dc.contributor.authoret al.
dc.date.issued2020
dc.description.abstractPulmonary complications in CTD are common and can involve the interstitium, airways, pleura and pulmonary vasculature. ILD can occur in all CTD (CTD-ILD), and mayvaryfromlimited,non-progressive lung involvemen to fulminant, life-threatening disease. Given the potential for major adverse outcomes in CTD-ILD, accurate diagnosis, assessment and careful consideration of therapeutic intervention are a priority. Limited data are available to guide management decisions in CTD-ILD. Autoimmune- mediated pulmonary inflammation is considered a key pathobiological pathway in these disorders, and immuno- suppressive therapy is generally regarded the cornerstone of treatment for severe and/or progressive CTD-ILD. How- ever, the natural history of CTD-ILD in individual patients can be difficult to predict, and deciding who to treat, when and with what agent can be challenging. Establishing realistic therapeutic goals from both the patient and clinician perspective requires considerable expertise. The document aims to provide a framework for clinicians to aid in the assessment and management of ILD in the major CTD. A suggested approach to diagnosis and monitoring of CTD-ILD and, where available, evidence-based, disease- specific approaches to treatment have been provided
dc.description.statementofresponsibilityAdelle S. Jee, Robert Sheehy, Peter Hopkins, Tamera J. Corte, Christopher Grainge, Lauren K. Troy … et al.
dc.identifier.citationRespirology, 2020; 26(1):1-29
dc.identifier.doi10.1111/resp.13977
dc.identifier.issn1323-7799
dc.identifier.issn1440-1843
dc.identifier.orcidReynolds, P.N. [0000-0002-2273-1774]
dc.identifier.urihttp://hdl.handle.net/2440/129709
dc.language.isoen
dc.publisherWiley
dc.rights© 2020 The Authors. Respirology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacifc Society of Respirology.
dc.source.urihttps://doi.org/10.1111/resp.13977
dc.subjectClinical diagnosis and management; collagen vas- cular disease; connective tissue disease; interstitial lung disease
dc.titleDiagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: a position statement from the Thoracic Society of Australia and New Zealand
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications